Pfizer decided to stop marketing Thelin, a drug for pulmonary arterial hypertension, in the EU, Australia and Canada, as well as suspend all clinical studies on the treatment after discovering a "potentially life-threatening idiosyncratic risk of liver injury." Pfizer said the overall benefit of Thelin, not yet approved by the FDA, "no longer outweighs the risk in the general population of PAH patients."

Full Story:

Related Summaries